AU6171000A - Method for releasing an agent from a red blood cell - Google Patents

Method for releasing an agent from a red blood cell Download PDF

Info

Publication number
AU6171000A
AU6171000A AU61710/00A AU6171000A AU6171000A AU 6171000 A AU6171000 A AU 6171000A AU 61710/00 A AU61710/00 A AU 61710/00A AU 6171000 A AU6171000 A AU 6171000A AU 6171000 A AU6171000 A AU 6171000A
Authority
AU
Australia
Prior art keywords
red blood
cells
blood cell
ultrasound
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61710/00A
Other languages
English (en)
Inventor
Roger Craig
Anthony Patrick Mchale
Ana Maria Rollan Haro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gendel Ltd
Original Assignee
Gendel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gendel Ltd filed Critical Gendel Ltd
Publication of AU6171000A publication Critical patent/AU6171000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU61710/00A 1999-07-23 2000-07-24 Method for releasing an agent from a red blood cell Abandoned AU6171000A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9917416 1999-07-23
GBGB9917416.1A GB9917416D0 (https=) 1999-07-23 1999-07-23
US14655699P 1999-07-30 1999-07-30
US60146556 1999-07-30
PCT/GB2000/002848 WO2001007011A1 (en) 1999-07-23 2000-07-24 Method for releasing an agent from a red blood cell

Publications (1)

Publication Number Publication Date
AU6171000A true AU6171000A (en) 2001-02-13

Family

ID=10857882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61710/00A Abandoned AU6171000A (en) 1999-07-23 2000-07-24 Method for releasing an agent from a red blood cell

Country Status (8)

Country Link
EP (1) EP1196143B1 (https=)
JP (1) JP2003505409A (https=)
AT (1) ATE318581T1 (https=)
AU (1) AU6171000A (https=)
CA (1) CA2378377A1 (https=)
GB (1) GB9917416D0 (https=)
MX (1) MXPA02000792A (https=)
WO (1) WO2001007011A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002856D0 (en) * 2000-02-08 2000-03-29 Gendel Limited Ultrasound sensitisation
CA2412544A1 (en) * 2000-07-24 2002-01-31 Gendel Limited Polypeptide delivery ii-2
WO2002040093A2 (en) 2000-11-17 2002-05-23 Gendel Limited Ablation of cells using combined electric field and ultrasound therapy
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
CA2438500C (en) * 2001-02-19 2009-09-08 Pola Chemical Industries Inc. Composition for electroporation
AU2003227960B2 (en) 2002-05-23 2008-10-30 Gendel Limited Ablation device
CA2929970C (en) 2013-12-20 2020-05-12 F. Hoffmann-La Roche Ag Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety
JP6629736B2 (ja) 2013-12-20 2020-01-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む、細胞を結合するのに有用な化合物
CN105917226B (zh) * 2013-12-20 2018-06-01 豪夫迈·罗氏有限公司 包含两个或多个疏水结构域和一个含有peg部分的亲水结构域的化合物用于稳定细胞的用途
CN110090309B (zh) * 2019-05-28 2022-05-31 上海大学 功能基化红细胞膜的制备方法
CN113088494B (zh) * 2021-04-13 2022-08-05 武汉大学 一种用于释放被红细胞仿生材料捕获的肿瘤细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655801C2 (de) * 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
US4935223A (en) * 1988-08-04 1990-06-19 Board Of Regents, The University Of Texas System Labeled cells for use in imaging
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
JPH02121931A (ja) * 1988-10-29 1990-05-09 Res Inst For Prod Dev 濃縮ヘモグロビンの製造方法
CA2248158A1 (en) * 1996-03-12 1997-09-18 The Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
EP0882448B1 (en) * 1997-05-05 2005-01-12 DIDECO S.r.l. Method of encapsulating biologically active agents within erythrocytes and apparatus therefor
DE19735460A1 (de) * 1997-08-16 1999-02-18 Rolf Prof Dr Med Zander Spül- oder Lagerungsflüssigkeit für Blutzellen

Also Published As

Publication number Publication date
MXPA02000792A (es) 2003-07-14
EP1196143B1 (en) 2006-03-01
JP2003505409A (ja) 2003-02-12
GB9917416D0 (https=) 1999-09-22
CA2378377A1 (en) 2001-02-01
WO2001007011A1 (en) 2001-02-01
EP1196143A1 (en) 2002-04-17
ATE318581T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
US6812204B1 (en) Delivery of an agent
US20040071664A1 (en) Delivery of an agent
US20010053549A1 (en) Loading method
Wang et al. Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implications
US20120034155A1 (en) Artificial cells
Carson et al. Gene therapy of carcinoma using ultrasound-targeted microbubble destruction
Wang et al. Targeted galectin-7 inhibition with ultrasound microbubble targeted gene therapy as a sole therapy to prevent acute rejection following heart transplantation in a Rodent model
EP1196143B1 (en) Use of an electric field for sensitising red blood cells to ultrasound
Mannell et al. Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles
Herbst et al. Delivery of stem cells to porcine arterial wall with echogenic liposomes conjugated to antibodies against CD34 and intercellular adhesion molecule-1
Qian et al. Ultrasound and magnetic responsive drug delivery systems for cardiovascular application
Gao et al. Engineering platelets with PDL1 antibodies and iron oxide nanoparticles for postsurgical cancer immunotherapy
Gopal et al. Effective drug targeting by erythrocytes as carrier systems
Patel et al. An overview of resealed erythrocyte drug delivery
Yadav et al. Resealed erythrocytes: as a drug delivery tool
WO2000007630A1 (en) Nucleic acid delivery
US20260034072A1 (en) Coated nanoparticles for the treatment of peripheral artery disease
Shilpi et al. Resealed Erythrocytes: A Biological Carrier for Drug Delivery
Mahaparale et al. Resealed RBC’s: Method, Evaluation, Route of Administration and Application
Pothula et al. Cellular Drug Delivery Systems
Pathak et al. Resealed erythrocytes: A novel carrier
Kumari et al. Resealed Erythrocyte: An Approach to Targeted Drug Delivery (A Review)
Gill Resealed erythrocytes as a potential drug carrier system
Rewar et al. Resealed Erythrocytes: As a Carrier for Drug Targeting
Suryasagar et al. A review ON resealed erythrocytes